Evolving marketplace dynamics, cuts in healthcare systems and governments, and the growing cost of innovation pose major challenges to demonstrating and delivering value effectively.
Powered by analytics and modeling across the entire life cycle, our commercial, HEOR, and access teams help you assess and clearly demonstrate value. We combine unmatched technical capabilities and advanced analytic methods with our deep relationships in the payer and health technology assessment (HTA) community to inform key decisions and maximize your product’s impact.
How we help our clients
Decision analytics and modeling
Health economics outcomes research
Market access and pricing
Real world evidence
US and EU payer engagement
US managed markets
Value communication software
Leveraging best-in-class capabilities in modeling & simulation, mathematics, and Bayesian statistics, we use advanced frameworks and proprietary software to:
- Navigate the most difficult trade-off decisions
- Inform strategic decisions for drug evaluation
- Quantify the impact of uncertainty around outcomes based agreements
- Removing the uncertainties between clinical trial efficacy
and real world effectiveness
The collection of Real World Data and use of Real World Evidence are having a profound impact on our industry. Today, it is common practice for regulators to use RWE to monitor post-market safety and to make regulatory decisions. And increasingly, sponsors are leveraging RWE to support clinical trial design and observational studies to generate treatment approaches. Likewise, healthcare systems are collecting and using RWE to substantiate coverage decisions.
Our industry-leading team is focused on RWE strategies and data analysis for commercial and scientific writings and applications.
The days of simply determining the market demand as a function of price and choosing the revenue or profit optimizing point are gone.
In our new environment, the idea of an explicit rationale, also known as the “value-based price” has become a prerequisite for enabling conversation with payers while policy-makers seem poised to limit the pricing corridors with increased government intervention.
Our unique platforms help you move performance contracts beyond pilots through decision-analytics and strategic scale.